Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of Yttrium-90 resin microspheres in unresectable colorectal cancer liver metastases after failure of standard therapy
CTR20232643Phase 4Active
- Sponsor
- Sirtex
- Start
- Nov 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 4 trial of yttrium (90Y) resin microspheres in colorectal cancer (CRC), sponsored by Sirtex. Started Nov 2023; status: active.
02
Drugs
yttrium (90Y) resin microspheres
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20232643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232643.